From the impact of Obamacare to cutting edge research, biotech buyouts to FDA decisions, The Motley Fool's health care team sits down each week to discuss the most fascinating developments in health care and their implications for long-term investors. In this week's edition, the team talks about the coming trend of penalizing unhealthy employees, the importance of drug branding, the avian flu outbreak, one stock investors need to watch, and more.
In the segment below, health care analyst Max Macaluso discusses how allergy season taught him a new lesson about Merck's (NYSE: MRK ) over-the-counter allergy drug Claritin and the marketing practices of big pharma companies.
Can Merck beat the patent cliff?
This titan of the pharmaceutical industry stumbled into 2013 and continues to battle patent expirations and pipeline problems. Is Merck still a solid dividend play, or should investors be looking elsewhere? In a new premium research report on Merck, The Fool tackles all of the company's moving parts, its major market opportunities, and reasons to both buy and sell. To find out more click here to claim your copy today.
The relevant video segment can be found between 1:44 and 3:17.